GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia

Investigator: Swaminathan Iyer, MD

Study Coordinator: Karen Woodard

Status: Open Not Enrolling Number: NCT01685892

Phone: 713.441.4332

IRB Number: Pro00009704


This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. The anticipated time on study treatment is 6 months.
More to Explore